The Combined Use of Hydroxymethylbutyrate and Branched-Chain Amino Acids to Counteract Uremic Sarcopenia.

FFSMP supplementation resulted in significant increases in quadriceps rectus femoris thickness (QRFT) in HD patients.

• The FFSMP consisted of free-form branched-chain amino acids, β-hydroxy-β-methylbutyrate (HMB), and zinc
• Patients received 10 g/day (two sachets) of FFSMP or placebo for 12 weeks
• The study was a randomized double-blind crossover design with 24 adult HD patients
• The two treatment periods were separated by an 8-week wash-out period (protocol code RS 29.23)

FFSMP supplementation led to a significant increase in fat-free mass percentage in HD patients.

• Body composition analysis was used to measure fat-free mass percentage
• The improvement was observed alongside the increase in QRFT muscle thickness
• The supplementation period lasted 12 weeks at a dose of 10 g/day
• No major adverse events occurred during the study

FFSMP supplementation was associated with reductions in oxidative stress and inflammatory biomarkers.

• Both oxidative stress indices and inflammatory markers were measured as outcomes
• Reductions in these biomarkers were observed during the FFSMP supplementation period compared to placebo
• HD patients are known to develop muscle wasting and chronic inflammation associated with functional decline
• The formulation included zinc, which may contribute to antioxidant effects

Routine biochemical parameters remained stable during FFSMP supplementation, with the exception of a decrease in pre-dialysis urea.

• The decrease in pre-dialysis urea was noted as the only significant change among routine biochemical parameters
• The stability of other biochemical parameters suggests the supplementation did not increase nitrogen load
• The FFSMP was described as providing 'targeted anabolic support without increasing nitrogen load'
• The formulation used free-form branched-chain amino acids rather than intact protein

Functional performance measures did not differ significantly between FFSMP and placebo treatment periods.

• Physical performance (PP) was measured as one of the primary outcomes
• No statistically significant differences in functional performance measures were observed between treatment periods
• The treatment duration was 12 weeks, which the authors acknowledge may be insufficient to detect changes in physical performance
• The authors concluded the FFSMP produced favorable changes 'without affecting short-term physical performance'

FFSMP supplementation led to improvements in selected SF-36 quality of life domains, specifically energy/fatigue and general health.

• Quality of life was assessed using the SF-36 questionnaire
• Improvements were noted specifically in the energy/fatigue and general health domains
• Not all SF-36 domains showed improvement; only selected domains were affected
• QoL was listed as one of the primary measured outcomes alongside muscle mass, strength, laboratory parameters, and physical performance

The study population consisted of adult hemodialysis patients who frequently develop uremic sarcopenia characterized by muscle wasting and chronic inflammation.

• 24 adult HD patients were enrolled in the randomized double-blind crossover study
• HD patients are described as frequently developing 'muscle wasting and chronic inflammation, conditions associated with functional decline and reduced quality of life'
• The condition is referred to as 'uremic sarcopenia' in the title
• The study protocol code was RS 29.23